Polypill and Nonalcoholic Steatohepatitis (PolyIran-L)
Polypill, which is being studied as an agent able to prevent cardiovascular events, contains atorvastatin and valsartan which might have beneficial effects in nonalcoholic steatohepatitis (NASH). This study aims to evaluate the possible benefits of polypill in NASH. Furthermore, cardiovascular mortality is a major cause of mortality in NASH patients. Polypill is expected to reduce cardiovascular mortality. We believe polypill is beneficial to patients with NASH by both preventing cardiovascular mortality and by improving liver condition.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effect of Polypill on the Natural History of Nonalcoholic Steatohepatitis|
- Changes in liver stiffness [ Time Frame: 5 years ] [ Designated as safety issue: No ]As measured by Fibroscan
- Side effects [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
- Changes in liver enzyme levels [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Cardiovascular events [ Time Frame: 5 years ] [ Designated as safety issue: No ]Includes myocardial infarction, cerebrovascular accident, sudden cardiac death, hospital admission due to cardiovascular events
- Compliance [ Time Frame: 5 years ] [ Designated as safety issue: No ]Percent of pills taken
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||March 2018|
|Estimated Primary Completion Date:||September 2017 (Final data collection date for primary outcome measure)|
Single daily dose of PolyPill and 6-monthly visits
Polypill taken once daily for 5 years. Each pill contains ASA 81 mg, atorvastatin 20 mg, hydrochlorthiazide 12.5 mg, valsartan 40 mg
Other Name: PolyPill 4-2
No Intervention: Control
Only 6-monthly visits
Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from steatosis to steatohepatitis (nonalcoholic steatohepatitis, NASH) to cirrhosis. Statins are competitive inhibitors of HMG CoA reductase, the rate-limiting step in cholesterol biosynthesis. They occupy a portion of the binding site of HMG CoA, blocking access of this substrate to the active site on the enzyme. A reduction in intrahepatic cholesterol leads to an increase in LDL receptor turnover that results from an enhanced rate of hepatic LDL receptor cycling. On the other hand recent studies have implicated several important cellular processes and signaling pathways that are affected by abnormal lipid metabolism, resulting in specific biochemical, histological, and clinical changes associated with NAFLD.
Maybe statins, as lipid lowering agents, and through their effect in reduction of intrahepatic cholesterol, can affect the abnormal lipid metabolism in NASH.
Angiotensin II could also promote fibrogenesis and inhibitors such as ARBs and ACE inhibitors might help halt the progression of NASH.
ASA and hydrochlorthiazide, other components of polypill, can help prevent cardiovascular morbidity and mortality which is increased in NASH.
|Iran, Islamic Republic of|
|Golestan Cohort Center|
|Gonbad, Golestan, Iran, Islamic Republic of|
|Study Chair:||Reza Malekzadeh, M.D.||Tehran University of Medical Sciences|
|Principal Investigator:||Shahin Merat, M.D.||Tehran University of Medical Sciences|